Your browser doesn't support javascript.
loading
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Girgis, Suzette; Lin, Shun Xin Wang; Pillarisetti, Kodandaram; Banerjee, Arnob; Stephenson, Tara; Ma, Xuewen; Shetty, Shoba; Yang, Tong-Yuan; Hilder, Brandi W; Jiao, Qun; Hanna, Brett; Adams, Homer C; Sun, Yu-Nien; Sharma, Amarnath; Smit, Jennifer; Infante, Jeffrey R; Goldberg, Jenna D; Elsayed, Yusri.
Afiliación
  • Girgis S; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA. SGirgis@its.jnj.com.
  • Lin SXW; Janssen Research & Development, Spring House, PA, USA.
  • Pillarisetti K; Janssen Research & Development, Spring House, PA, USA.
  • Banerjee A; Janssen Research & Development, Spring House, PA, USA.
  • Stephenson T; Janssen Research & Development, Spring House, PA, USA.
  • Ma X; Janssen Research & Development, Spring House, PA, USA.
  • Shetty S; Janssen Research & Development, Spring House, PA, USA.
  • Yang TY; Janssen Research & Development, Spring House, PA, USA.
  • Hilder BW; Janssen Research & Development, Spring House, PA, USA.
  • Jiao Q; Janssen Research & Development, Spring House, PA, USA.
  • Hanna B; Janssen Research & Development, Spring House, PA, USA.
  • Adams HC; Janssen Research & Development, Spring House, PA, USA.
  • Sun YN; Janssen Research & Development, Spring House, PA, USA.
  • Sharma A; Janssen Research & Development, Tokyo, Japan.
  • Smit J; Janssen Research & Development, Spring House, PA, USA.
  • Infante JR; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA.
  • Goldberg JD; Janssen Research & Development, 920 Route 202, Raritan, NJ, 08869, USA.
  • Elsayed Y; Janssen Research & Development, Spring House, PA, USA.
Target Oncol ; 17(5): 609, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35913648

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Target Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Francia